Hannah Chudleigh

Researchers may have found a potential treatment for congenital heart defects in a surprising source: an over-the-counter cough suppressant. Know more here.
Patient enrollment for the clinical trial, which was testing Atara’s autologous chimeric antigen receptor (CAR) T-cell immunology therapy called ATA2271, has been paused.
In addition to massive layoffs – around 60% of its workforce – Yumanity also said it is considering “strategic alternatives” to its financial woes, including the possibility of selling or merging.
By the end of the CREDIT-1 study, patients experienced a significant reduction in low-density lipoprotein cholesterol compared to the placebo group.
Antibody research on cancer and neurological diseases is prioritized in series of biopharma research agreements.
Six months after the one-time treatment, 47% of patients in Cohort 1 demonstrated a promising two-step or greater improvement in their diabetic retinopathy.
The fund will be used to target partnerships with promising early-stage biotechnology to enhance Fujifilm’s life sciences portfolio.
kENUP had called the mRNA vaccine efforts in Africa “doomed to fail” since the project likely infringes on BioNTech and Moderna patents on the vaccine.
In this process, scientists used ultrasonic waves—the same low-frequency waves used in medical sonograms—to activate a specific group of genetically marked cells.
Statistically significant weight loss and liver fat reduction were seen across all dosage groups—with no changes to diet or exercise.
The new funds will go toward advancing Congruence’s Revenir™ platform, a computational tool that models diseases that come from cellular proteins misfolding in order to understand them better.
Revealed in an article published in Science magazine, this new variant of HIV was discovered in individuals in the Netherlands, Belgium and Switzerland.
On Thursday, Unity Biotechnology announced that it is cutting 50% of its workforce, mainly in the research department.
A new study published in the journal Nature found that two patients with leukemia who were treated with CAR T-cell therapy are still in remission 10 years later.
The portfolio of STING inhibitors is designed to treat autoimmune and inflammatory diseases.